Web Analytics Made Easy - Statcounter
rivijera.me :: Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

Amylyx Pharmaceuticals, Inc. (AMLX) Discusses LUCIDITY Results and Avexitide Potential in Post-Bariatric Hypoglycemia Transcript

2026-11-16 00:13 via seekingalpha.com

Camille Bedrosian
Chief Medical Officer

Okay. Good morning, everyone. Welcome, and thank you so much for joining us today, both here in the room as well as on the webcast. I'm Camille Bedrosian, Chief Medical Officer at Amylyx.

We are so excited to be here at ObesityWeek as well as having the opportunity to share with all of you our -- the aspects of post-bariatric hypoglycemia as well as the potential of avexitide, an investigational, first-in-class GLP-1 receptor antagonist with FDA Breakthrough Therapy designation. Throughout today's program, you'll hear from leading PBH experts as they discuss the burden of PBH, the unmet need as well as the Phase III LUCIDITY results in more detail.

Before we begin, as you know, we will be making some forward-looking statements during the presentation. So please refer to the slide that you're seeing here as well as to the information that's on our investor website.

So here is the agenda for today. First, we'll begin with a short video, very important to hear from a member of the PBH community, who shares with us her experience living with the condition. It will raise quite a bit of awareness about what people live through with this condition. Next, we'll hear from Dr. Zeb Saeed from Brigham and Women's Hospital, who will provide an overview of PBH, including patient burden, clinical challenges and ongoing unmet medical need. Then we'll hear from Dr. Marilyn Tan, who will review the LUCIDITY results presented earlier


Source: https://seekingalpha.com/article/4968409-amylyx-pharmaceuticals-inc-amlx-discusses-lucidity-results-and-avexitide-potential-in-post?source=feed_all_articles

Free Counters